Renalytix (DE:2O9)
FRANKFURT:2O9
2O9 Stock Chart & Stats
€0.10
>-€0.01(-4.41%)
At close: 4:00 PM EST
€0.10
>-€0.01(-4.41%)
Day’s Range― - ―
52-Week Range€0.01 - €0.13
Previous CloseN/A
Volume0.00
Average Volume (3M)17.00
Market Cap
€9.11M
Enterprise Value€26.40M
Total Cash (Recent Filing)€9.63M
Total Debt (Recent Filing)€8.21M
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding437,018,680
10 Day Avg. Volume52
30 Day Avg. Volume17
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-1.38
Price to Sales (P/S)3.23
P/FCF Ratio-0.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product Differentiation: KidneyIntelXRenalytix’s KidneyIntelX pairs biomarkers with AI-driven algorithms, creating a differentiated diagnostic platform. This combination raises clinical switching costs, supports integration into care pathways, and drives recurring test-volume revenue as adoption by health systems scales over months to years.
Improving Revenue And Gross MarginA 26% revenue increase with a step-change in gross margin to ~40% indicates improving unit economics and pricing or cost efficiencies. If sustained, these trends materially reduce the funding needed per incremental test and provide a clearer pathway toward operating leverage as volumes grow.
Modest Absolute Debt BurdenAbsolute debt of ~8.3m limits fixed financing costs and interest exposure compared with highly leveraged peers. This modest debt level affords some flexibility in capital structure and reduces immediate solvency pressure, easing near-term liquidity management while strategic initiatives advance.
Bears Say
Heavy Operating Cash BurnSustained negative operating and free cash flow (~-17.9m) means the business relies on external financing to fund operations and commercial expansion. Continued cash burn increases dilution risk, constrains investment flexibility, and can limit the company’s ability to scale sales and lab capacity sustainably.
Negative Shareholders' EquityNegative equity reflects cumulative losses and a stressed capital base, restricting access to conventional financing and increasing dependence on dilutive capital or distressed financing. It also weakens the balance sheet’s ability to absorb operational setbacks or prolonged commercialization timelines.
Losses Far Exceed Current RevenueExtremely large net losses versus modest revenue indicate the current cost base is structurally well above revenue. Achieving profitability requires significant scale-up in test volumes and sustained margin improvements; otherwise the business will remain dependent on recurrent funding rounds.
Renalytix News
2O9 FAQ
What was Renalytix’s price range in the past 12 months?
Renalytix lowest stock price was €0.01 and its highest was €0.13 in the past 12 months.
What is Renalytix’s market cap?
Renalytix’s market cap is €9.11M.
When is Renalytix’s upcoming earnings report date?
Renalytix’s upcoming earnings report date is Nov 03, 2026 which is in 150 days.
How were Renalytix’s earnings last quarter?
Renalytix released its earnings results on Mar 26, 2026. The company reported -€0.019 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.019.
Is Renalytix overvalued?
According to Wall Street analysts Renalytix’s price is currently Overvalued.
Does Renalytix pay dividends?
Renalytix does not currently pay dividends.
What is Renalytix’s EPS estimate?
Renalytix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Renalytix have?
Renalytix has 437,018,680 shares outstanding.
What happened to Renalytix’s price movement after its last earnings report?
Renalytix reported an EPS of -€0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.636%.
Which hedge fund is a major shareholder of Renalytix?
Currently, no hedge funds are holding shares in DE:2O9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Renalytix
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Technical Analysis
EKF Diagnostics Holdings
―
Genedrive
―
Oxford BioDynamics
―
Proteome Sciences
―
Verici Dx Plc
―
Options Prices
Currently, No data available
---